glp 1 oral fda approved Semaglutide Gets Approval for CV Event Reduction in High-risk Diabetes Patients FDA Approves First Oral GLP-1
Description
2/2024Falsified OZEMPIC (semaglutide) Identified in the WHO Regions of Americas and Europe

If you do not have metabolic disease, the idea of using GLP-1 purely for dementia prevention is more speculative
En el grupo activo 33,1% perdi ms del 10% de peso mientras en el grupo placebo este porcentaje llego solo a 10,6%

Mild redness, itching, or a localised Mounjaro skin rash does not always mean treatment needs to be stopped

doi: 10.1016/j.bmcl.2015.12.024
